ZTS
Zoetis Inc. NYSE$112.68
Mkt Cap $47.6B
52w Low $112.10
1.0% of range
52w High $172.23
50d MA $119.85
200d MA $132.20
P/E (TTM)
18.9x
EV/EBITDA
15.5x
P/B
15.2x
Debt/Equity
2.9x
ROE
80.2%
P/FCF
24.4x
RSI (14)
—
ATR (14)
—
Beta
0.97
50d MA
$119.85
200d MA
$132.20
Avg Volume
4.1M
About
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biologica…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | 1.40 | 1.48 | +5.7% | 125.64 | +0.8% | +0.8% | -0.1% | +2.8% | +1.3% | +2.5% | -6.0% | — |
| Nov 4, 2025 | AMC | 1.62 | 1.70 | +4.9% | 124.46 | -0.2% | -3.2% | -3.9% | -3.4% | -3.8% | -3.5% | -3.3% | — |
| Aug 5, 2025 | AMC | 1.62 | 1.76 | +8.6% | 146.12 | +0.1% | +0.3% | +1.5% | +0.8% | +2.0% | +2.5% | +4.8% | — |
| May 6, 2025 | AMC | 1.41 | 1.48 | +5.0% | 149.87 | +1.2% | +4.1% | +7.9% | +6.3% | +8.0% | +7.0% | +12.5% | — |
| Feb 13, 2025 | AMC | 1.37 | 1.40 | +2.2% | 164.93 | -0.6% | -4.5% | -5.1% | -5.0% | -4.6% | -2.7% | +0.1% | — |
| Nov 4, 2024 | AMC | 1.46 | 1.58 | +8.2% | 175.18 | -0.4% | +0.1% | -2.7% | -0.5% | +0.9% | +0.6% | +0.1% | — |
| Aug 6, 2024 | AMC | 1.49 | 1.56 | +4.7% | 185.29 | +0.4% | -0.3% | +1.6% | -0.0% | -0.8% | +1.7% | +0.7% | — |
| May 2, 2024 | AMC | 1.34 | 1.38 | +3.0% | 167.23 | +1.9% | -0.1% | -0.8% | +0.7% | -1.4% | +0.5% | +3.1% | — |
| Feb 13, 2024 | AMC | 1.32 | 1.24 | -6.1% | 183.49 | +0.9% | +0.3% | +3.4% | +2.7% | +1.7% | +2.7% | -5.2% | — |
| Nov 2, 2023 | AMC | 1.36 | 1.36 | +0.0% | 160.91 | +2.1% | +0.8% | +1.4% | +3.9% | +6.2% | +6.0% | +13.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $117.87 | $117.23 | -0.5% | -1.0% | -3.4% | -2.5% | -3.1% | — |
| Feb 13 | BofA Securities | Maintains | Neutral → Neutral | — | $125.64 | $126.67 | +0.8% | +0.8% | -0.1% | +2.8% | +1.3% | +2.5% |
| Jan 22 | Piper Sandler | Downgrade | Overweight → Neutral | — | $125.08 | $124.27 | -0.6% | -0.5% | -0.8% | -0.9% | -0.1% | -2.5% |
| Dec 3 | BTIG | Maintains | Buy → Buy | — | $124.44 | $125.28 | +0.7% | -1.5% | -3.2% | -4.7% | -5.0% | -7.0% |
| Nov 18 | Stifel | Maintains | Hold → Hold | — | $118.80 | $118.43 | -0.3% | -0.6% | -1.4% | -2.4% | +2.7% | +3.4% |
| Nov 12 | BTIG | Maintains | Buy → Buy | — | $120.12 | $120.18 | +0.1% | +0.9% | +0.9% | +0.6% | -1.1% | -1.6% |
| Nov 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $120.24 | $120.43 | +0.2% | -0.4% | -0.1% | +0.8% | +0.8% | +0.5% |
| Nov 5 | UBS | Maintains | Neutral → Neutral | — | $124.46 | $124.20 | -0.2% | -3.2% | -3.9% | -3.4% | -3.8% | -3.5% |
| Nov 5 | JP Morgan | Maintains | Overweight → Overweight | — | $124.46 | $124.20 | -0.2% | -3.2% | -3.9% | -3.4% | -3.8% | -3.5% |
| Oct 20 | UBS | Maintains | Neutral → Neutral | — | $144.06 | $143.87 | -0.1% | +0.7% | +1.4% | +2.1% | +1.6% | +1.3% |
Recent Filings
8-K
ZOETIS INC. -- 8-K Filing
Zoetis reported Q4 and full-year 2025 results and issued 2026 guidance, providing investors with updated financial performance metrics and forward-looking expectations for the animal health company.
Feb 12
8-K · 7.01
! Medium
ZOETIS INC. -- 8-K 7.01: Regulation FD Disclosure
Zoetis declared a $0.53 per share dividend payable June 2, 2026, to shareholders of record April 20, 2026, providing steady income returns to investors.
Feb 5
Data updated apr 27, 2026 11:51am
· Source: massive.com